According to a recent clinical trial, for PD-L1-positive melanoma patients with brain metastasis who received nivolumab plus ipilimumab, the intracranial clinical benefit rate was 57%, objective response rate was 55%, complete response rate was 26%, with 6-, 9-, and 12-months survival of 92.3, 82.8, and 81.5%, respectively. The gene discussed is CD274; the disease is melanoma.